Invitrogen™ IL-1 alpha/beta (Lutikizumab Biosimilar) Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA542121	100 μg

Catalog No. PIMA542121 Supplier Invitrogen™ Supplier No. MA542121

Description

Human Recombinant Monoclonal Antibody

Endotoxin level <0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt. Isotype of this product is: IgG1, kappa (DVD-Ig) This product is a Humanized mouse antibody.

IL-1a (Interleukin-1 alpha) is a proinflammatory cytokine produced mainly by monocytes, macrophages, and dendritic cells. Encoded by the IL1A gene on chromosome 2q13, it signals through IL-1RI and IL-1RII receptors, which are shared with IL-1B. IL-1a plays a key role in innate immunity by inducing other proinflammatory cytokines and initiating acute-phase responses. It regulates NF-kB and MAPK pathways and stimulates expression of IL-6, COX-2, and nitric oxide. IL-1a is synthesized as a proprotein that can be processed and released upon cell injury, contributing to inflammation and apoptosis. Its activity is controlled by IL-1 receptor antagonist (IL-1RA), which competitively blocks receptor binding. Elevated IL-1a levels are associated with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis. The IL1A gene is part of an interleukin-1 family gene cluster on chromosome 2.IL-1b (Interleukin-1 beta) is another potent proinflammatory cytokine produced by similar immune cells. It is synthesized as an inactive 31 kDa precursor (pro-IL-1b) in response to inflammatory stimuli. Activation requires inflammasomes, which trigger caspase-1-mediated cleavage into the active 17 kDa form. Unlike many secreted proteins, IL-1b lacks a classical signal peptide and is released through nontraditional secretion pathways. IL-1b signals through IL-1RI and IL-1RII and is also regulated by IL-1RA. It promotes cytokine production and acute-phase responses during infection and tissue injury. Elevated IL-1b levels are linked to numerous chronic inflammatory conditions, and IL-1b-neutralizing therapies have important clinical applications.

Specifications

• Antigen: IL-1 alpha/beta (Lutikizumab Biosimilar)
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 0.84 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: ABT-981
• Host Species: Human
• Immunogen: Human IL1A /IL1B.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1 κ
• Target Molecule: Chemical